Evidence map›Paper›PMID 39252901›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Adaptive Deep Brain Stimulation in Parkinson's Disease: A Delphi Consensus Study.

M Guidetti, T Bocci, M De Pedro Del Álamo, G Deuschl, A Fasano, R Martinez Fernandez, C Gasca-Salas, C Hamani, J K Krauss, A A Kühn and 17 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

M Guidetti"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milan, Italy.ORCID 0000-0002-4562-009X
T Bocci"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milan, Italy.
M De Pedro Del ÁlamoHM CINAC, Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.
G DeuschlDepartment of Neurology University Hospital Schleswig-Holstein, Campus Kiel and Christian Albrechts-University of Kiel Kiel Germany.
A FasanoKrembil Research Institute, University Health Network, Toronto, ON, Canada.
R Martinez FernandezHM CINAC, Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.ORCID 0000-0002-0305-013X
C Gasca-SalasHM CINAC, Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.ORCID 0000-0001-7411-8106
C HamaniSunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, M4N 3M5, ON, Canada.
J K KraussDepartment of Neurosurgery, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-0675-9064
A A KühnDepartment of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
P LimousinDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, United Kingdom.
S LittleMovement Disorders and Neuromodulation Centre, University of California San Francisco, San Francisco, California, USA.
A M LozanoKrembil Research Institute, University Health Network, Toronto, ON, Canada.
N V Maiorana"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milan, Italy.
S MarcegliaDepartment of Engineering and Architecture, University of Trieste, Trieste, Italy.
M S OkunDepartment of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, United States.
S Oliveri"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milan, Italy.
J L OstremMovement Disorders and Neuromodulation Centre, University of California San Francisco, San Francisco, California, USA.
E ScelzoClinical Neurology Unit, "Azienda Socio-Sanitaria Territoriale Santi Paolo e Carlo", Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milan, Italy.
A SchnitzlerInstitute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
P A StarrUCSF Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Y TemelDepartment of Neurosurgery, Maastricht University Medical Center, Maastricht, Netherlands.
L TimmermannDepartment of Neurology, University Hospital of Marburg, Marburg, Germany.
G TinkhauserDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
V Visser-VandewalleDepartment of Stereotactic and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
J VolkmannDepartment of Neurology, University Hospital Würzburg, Würzburg, Germany.
A Priori"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milan, Italy.

Funding

Defining Targets for Tic Detection and Suppression in Tourette Syndrome Deep Brain StimulationUH3NS119844 · NINDS · UNIVERSITY OF FLORIDA · PI BUTSON, CHRISTOPHER R, GUNDUZ, AYSEGUL · 2021 to 2025
$5.0M
Web-based Automated Imaging Differentiation of ParkinsonismU01NS119562 · NINDS · UNIVERSITY OF FLORIDA · PI BARMPOUTIS, ANGELOS, OKUN, MICHAEL S · 2021 to 2025
$4.8M
Mobile Decision Support System for Nurse Management of Neuromodulation TherapyR01NR014852 · NINR · UNIVERSITY OF UTAH · PI BUTSON, CHRISTOPHER R, OKUN, MICHAEL S · 2015 to 2019
$2.9M
Determining the circuits and signals of sleep dysfunction in Parkinson's disease through chronic intracranial recordings and closed-loop Deep Brain StimulationR01NS131405 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Simon Little · 2023 to 2026
$2.6M
THE HUMAN THALAMOCORTICAL NETWORK IN TOURETTE SYNDROMER01NS096008 · NINDS · UNIVERSITY OF FLORIDA · PI GUNDUZ, AYSEGUL, OKUN, MICHAEL S · 2016 to 2020
$1.8M
Uncovering the neurophysiology of motivation in Parkinson™s disease with implanted adaptive brain stimulationK23NS120037 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LITTLE, SIMON · 2021 to 2024
$809k
University of Florida R25 Early Research Program for Neurology and Neurosurgery ResidentsR25NS108939 · NINDS · UNIVERSITY OF FLORIDA · PI HOH, BRIAN LIM, OKUN, MICHAEL S · 2019 to 2024
$537k
NINDS NIH HHS K23 NS120037NINDS NIH HHS R01 NS096008NINDS NIH HHS R01 NS131405NINDS NIH HHS R25 NS108939NINDS NIH HHS U01 NS119562NINDS NIH HHS UH3 NS119844NINR NIH HHS R01 NR014852Wellcome Trust
6 · The paper itself

Abstract

Importance: If history teaches, as cardiac pacing moved from fixed-rate to on-demand delivery in in 80s of the last century, there are high probabilities that closed-loop and adaptive approaches will become, in the next decade, the natural evolution of conventional Deep Brain Stimulation (cDBS). However, while devices for aDBS are already available for clinical use, few data on their clinical application and technological limitations are available so far. In such scenario, gathering the opinion and expertise of leading investigators worldwide would boost and guide practice and research, thus grounding the clinical development of aDBS. Observations: We identified clinical and academically experienced DBS clinicians (n=21) to discuss the challenges related to aDBS. A 5-point Likert scale questionnaire along with a Delphi method was employed. 42 questions were submitted to the panel, half of them being related to technical aspects while the other half to clinical aspects of aDBS. Experts agreed that aDBS will become clinical practice in 10 years. In the present scenario, although the panel agreed that aDBS applications require skilled clinicians and that algorithms need to be further optimized to manage complex PD symptoms, consensus was reached on aDBS safety and its ability to provide a faster and more stable treatment response than cDBS, also for tremor-dominant Parkinson's disease patients and for those with motor fluctuations and dyskinesias. Conclusions and Relevance: Despite the need of further research, the panel concluded that aDBS is safe, promises to be maximally effective in PD patients with motor fluctuation and dyskinesias and therefore will enter into the clinical practice in the next years, with further research focused on algorithms and markers for complex symptoms.

Indexed as

adaptive DBSclosed-loop DBSDBSDeep Brain StimulationDelphi consensusmovement disordersneuromodulationParkinson’s disease

Identifiers

PMID39252901
PMCPMC11383503

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.